Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy (ACR20) of Rob 803
administered orally once daily for 12 weeks in combination with a stable dose of methotrexate
in subjects with moderate or severe active RA.